Mucormycoses.

Dimitrios Farmakiotis, Dimitrios P Kontoyiannis

Journal: Infectious disease clinics of North America 2016;30(1):143-63

PMID: 26897065

Full Text on Elsevier Science View on PubMed

Abstract

Life-threatening infections from virulent, angioinvasive molds of the order Mucorales are being recognized with increasing frequency in immunosuppressed hosts. Advances in the understanding of pathogenesis, early diagnosis, and the recent availability of active, nontoxic drugs have improved the prospects for effective control and even cure of this devastating infection. However, rates of delayed diagnosis and mortality are still high, partially because of the low yield and complexity of culture-based and molecular diagnostic methods. Therefore, there is an urgent need for novel diagnostic modalities and effective therapeutic approaches.

Address: Division of Infectious Diseases, Rhode Island Hospital, Warren Alpert Medical School of Brown University, 593 Eddy Street, Providence, RI 02903, USA. Electronic address: [email protected].; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

DOI: 10.1016/j.idc.2015.10.011

Link outs

Free resources

Other Literature Sources:

https://scite.ai/reports/26897065

Subscription / membership required

Full Text Sources:

MeSH Terms: Antifungal Agents, Humans, Immunocompromised Host, Mucormycosis